title: Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008.
abstract: OBJECTIVE
  To determine the association of hydroxymethylglutarylcoenzyme A (HMG Co-A) reductase inhibitor (statin) use with the prevalence of age-related macular degeneration (AMD).
  
  
  METHODS
  This cross-sectional study included 5604 participants in the National Health and Nutrition Examination Survey (NHANES) from 2005 to 2008, ≥ 40 years of age, who were ascertained with regard to the diagnosis of AMD, the use of statins, and comorbidities and health-related behaviors such as smoking.
  
  
  RESULTS
  The mean age of participants denying or confirming a history of AMD was 68 (SEM 0.90) and 55 (SEM 0.36) years, respectively. Individuals 68 years of age or older who were classified as long-term users of statins had statistically significant less self-reported AMD (odds ratio (OR) 0.64, 95% confidence interval (CI) 0.49-0.84; P=0.002), after adjusting for potential confounding variables. No significant association was found between the prevalence of AMD and statin consumption among subjects between 40 and 67 years of age (OR 1.61, 95% CI 0.85-3.03; P=0.137).
  
  
  CONCLUSIONS
  Our results suggest a possible beneficial effect of statin intake for the prevention of AMD in individuals 68 years of age or older.
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: D T Q
authors: DT
authors: Barbosa
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: T S
authors: TS
authors: Mendes
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: H R
authors: HR
authors: Cíntron-Colon
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: S Y
authors: SY
authors: Wang
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: R B
authors: RB
authors: Bhisitkul
authors: Department of Ophthalmology, Stanford University, Stanford, CA, USA.
authors: K
authors: K
authors: Singh
authors: Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA.
authors: S C
authors: SC
authors: Lin
mesh_terms: D000328:Adult; D000368:Aged; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D016015:Logistic Models; D008268:Macular Degeneration / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D015995:Prevalence; D012307:Risk Factors; D014481:United States / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors